ABVC BioPharma, Inc. (ABVC) Q2 2026 Earnings: Revenue $0K
ABVC — Q2 2026 Financial Report Analysis
Q2 · Fiscal year 2026 · Published by Pham Hop
ABVC BioPharma's Q2 2026 net loss fell 67% to $0.74 million as a year-ago stock payout to advisors did not repeat, but it ended June with just $31,944 in cash, a $5.28 million working-capital deficit and a going-concern warning.
Revenue
$0K
Net income
-$737K
+67.3% YoY
Diluted EPS
$-0.03
+76.9% YoY
ABVC BioPharma, a Fremont, California-based developer of plant-derived drugs and an eye-surgery device, cut its second-quarter 2026 net loss by about two-thirds, to $0.74 million attributable to shareholders from $2.26 million a year earlier. The improvement came almost entirely from paying far less stock to consultants, not from any new income: revenue was $0 in both quarters. The bigger story is the balance sheet. The company ended June with $31,944 in cash and a working-capital deficit of $5.28 million, and its own filing says there is "substantial doubt" about whether it can keep operating as a going concern.
At a glance
Cash of $31,944 on June 30, 2026, down from $1.33 million (including restricted cash) at the start of the year. At the first half's average operating cash burn of about $190,000 a month, that is under a week of spending.
Net loss attributable to ABVC of $736,934, down 67% year on year, because stock-based compensation (pay handed out in shares instead of cash) fell to $253,041 from $1,571,613.
Research and development spending was just $22,707 for the quarter (about 3% of operating costs), a sign that clinical work is largely paused while the company conserves cash.
The quarter in numbers
All figures are for the three months ended June 30, from the company's unaudited 10-Q.
Metric
Q2 2026
Q2 2025
YoY Change
Revenue
$0
$0
n/a
Total operating expenses
$779,526
$2,294,983
-66.0%
Read 0 community reports on ABVC BioPharma, Inc., or write your own.Write a report
of which stock-based compensation
$253,041
$1,571,613
-83.9%
of which selling, general & administrative
$503,778
$690,094
-27.0%
of which research & development
$22,707
$33,276
-31.8%
Net loss (total)
$(810,481)
$(2,332,833)
Loss narrowed 65.3%
Net loss attributable to ABVC
$(736,934)
$(2,257,022)
Loss narrowed 67.3%
Loss per share (basic and diluted)
$(0.03)
$(0.13)
Loss narrowed 76.9%
Weighted average shares
26,058,884
17,386,536
+49.9%
Cash and cash equivalents (period end)
$31,944
$681,480 (Dec 31, 2025)
-95.3% vs year-end
Working capital (period end)
$(5,282,776)
$(3,662,633) (Dec 31, 2025)
Deficit widened $1.62M
Operating margin (operating profit as a share of revenue) is not shown because with zero revenue it cannot be calculated. For the first six months of 2026, the net loss attributable to ABVC was $2,297,176 ($0.09 per share), against $3,099,097 ($0.19 per share) a year earlier.
What drove the smaller loss
The filing is direct about it: operating expenses fell "mainly due to the Company hired certain consultants and advisors for business opportunity and financial advisory services during the three months ended June 30, 2025, leading to higher stock-based compensation expenses." In other words, the year-ago quarter was inflated by a one-off wave of share-based payments to advisors, and that did not repeat.
Stripping stock pay out, the cash-type costs of running the company (SG&A plus R&D) were $526,485 in the quarter versus $723,370 a year ago, down 27%. That is a real reduction, but over the full six months the same figure fell only 4% ($1,311,583 versus $1,367,602), so the second-quarter drop partly reflects timing rather than a lasting new cost base.
Below the operating line, interest expense fell to $42,323 from $129,413 as the company repaid bank loans. Offsetting that, the foreign-exchange gain shrank to $11,378 from $136,148 (ABVC has operations in Taiwan, so currency moves change the dollar value of its Taiwanese balances). The year-ago quarter also carried a $23,627 income-tax charge that did not recur.
What the headline numbers hide
The per-share improvement is flattered by dilution. Weighted shares outstanding rose 50% to about 26.1 million. Had the share count stayed at last year's 17.4 million, the Q2 loss would have been about $0.04 per share rather than $0.03. Some of the "better" EPS simply comes from spreading the loss over more shares, which were issued to raise money and pay for services.
A large part of the loss is paid in shares, not cash. Over six months, the net loss was $2.50 million but operating cash outflow was $1.14 million. The gap is mostly $1.04 million of stock-based compensation, which does not use cash but does dilute existing shareholders. Even rent is largely paid in stock: of the lease payments in the first half, $220,594 was settled in shares and only $58,947 in cash.
Cash went out faster than the operating burn alone suggests. Cash plus restricted cash fell $1.30 million in six months. Beyond the $1.14 million operating outflow, the company repaid $691,299 of short-term loans (the CTBC bank loan balance of $636,000 went to zero, and the $645,505 of restricted cash on the December balance sheet is gone), while raising only $319,492 from private placements and $102,000 from warrant exercises, versus $1.87 million from private placements in the same period of 2025.
Money is flowing to related companies. In the first half ABVC paid $668,403 toward a long-term investment (which MD&A ties to ForSeeCon Eye), lent $147,572 to related parties and put $32,000 into a related-party convertible note, funded largely by $793,567 of repayments from related parties. Management says it gave "short-term operational funding support to BioFirst", the Taiwanese partner building a manufacturing plant for the Vitargus eye device, to "safeguard the value of the Company's existing investment." For a company with $31,944 in the bank, cash directed to affiliates is a meaningful choice.
Unpaid bills are piling up in current liabilities. Of $4.20 million in accrued expenses, $1.74 million is owed to outside contractors for manufacturing and process development work, and $1.36 million is accrued pay owed to directors and officers. The MD&A says the Lind convertible notes were fully repaid, yet the balance sheet still carries a $500,000 accrued "cash portion of the Lind Note repayments", so that obligation has not yet been settled in cash.
Most of the assets are not easy to turn into cash. Of $19.40 million in total assets, $12.83 million is property and equipment, largely land in Taiwan, and another $2.49 million is long-term investments in affiliated private companies. Current assets are only $411,729 against current liabilities of $5.69 million.
Reporting controls remain weak. Management concluded disclosure controls were "not effective" as of June 30, 2026, citing the material weakness that led to restating 2025 results. During the quarter it also found a new deficiency in vetting an external financial-reporting advisor, and terminated that advisor after finding it had not caught "certain regulatory or disciplinary matters" on time. The first-quarter 10-Q was also filed late, after a notice of late filing on May 15, 2026.
Takeaway: The 67% smaller loss is real but mostly reflects the absence of a year-ago stock payout to advisors; what matters for ABVC is that it closed June with $31,944 of cash against $5.69 million of short-term obligations, so its survival depends on raising new money or collecting licensing payments, not on its drug pipeline.
Pipeline status: little clinical spending, several programs paused
ABVC's model is to take plant-derived drug candidates licensed from Asian research institutions through early (Phase I and II) human trials, then license them to larger drugmakers for the costly final-stage trials. Per the 10-Q:
Vitargus (ABV-1701), a gel used to hold the retina in place after eye surgery: the Phase II study in Australia and Thailand "was put on hold due to Serious Adverse Events" in patients at the Thailand sites. The company believes a modified surgical procedure may be the cause and is producing a new investigational batch before any restart. Partner BioFirst is building a GMP (drug-quality) manufacturing plant in Hsinchu, Taiwan, "with targeted completion in 2026."
ABV-1504 (major depressive disorder): Phase II completed; the company says it is focused on licensing it out.
ABV-1505 (adult ADHD): Phase II Part 2 has enrolled 69 subjects; a clinical study report was submitted in March 2025.
ABV-1519 (non-small cell lung cancer, Phase I/II in Taiwan) and ABV-1703 (pancreatic cancer, Phase II at Cedars-Sinai): both "expected to begin in the fourth quarter of 2026."
ABV-2002 (corneal storage solution): "Further clinical development has been temporarily suspended due to funding constraints."
With R&D at $55,807 for the whole first half, starting two new trials in the fourth quarter would require funding the company does not currently have on its balance sheet.
Licensing income: large contracts, little cash
ABVC has licensing deals on paper worth much more than its market footprint suggests: the ForSeeCon Eye agreement for Vitargus includes a $3.5 million second milestone that can be paid in increments, and the 2024 OncoX agreements each call for $6.25 million in cash or OncoX shares valued at $5 each. But the filing states there was "no cash received" from ForSeeCon in the first half of either 2025 or 2026, and revenue was zero. Both counterparties are affiliated with the ABVC group (management describes them as "equity investments" being aligned with its strategy). Until these contracts produce cash rather than paper, they do not address the liquidity problem.
Other corporate moves
BioKey spin-off (partial): On June 22, 2026 ABVC agreed to separate BioKey Cayman, parent of its California contract manufacturing and development subsidiary, and distribute about 4.5 million BioKey Cayman shares (roughly 15%) to ABVC shareholders while keeping about 85%. The distribution was scheduled for August 3, 2026 "but was postponed due to outstanding tax, administrative and regulatory matters"; no new date has been set.
Taiwan farmland: On July 20, 2026, subsidiary Yun Zhi Yi completed the ownership transfer registration for five farmland parcels in Puli, Nantou County, after Taiwan's Ministry of Agriculture approved the purchase on May 15.
Did last time's read hold up?
This is our first published analysis of ABVC, so there is no earlier outlook to check against.
Outlook: the next few months are about funding
Management gives no financial guidance. Its stated plan to address the going-concern doubt is to (1) collect amounts due under licensing and collaboration agreements, (2) raise money through private or public offerings, (3) cut operating expenses and (4) reduce debt. It "anticipates that ongoing affiliate integration and project execution will contribute positively to cash flows over the next 12 months," but the first half showed no licensing cash and falling equity raises.
Our read: with under a week of average cash burn on hand at quarter end, ABVC will almost certainly need to issue more shares (diluting existing holders further), borrow from insiders or related parties (it already received a net $153,835 from related parties in the first half), or collect licensing cash before year-end. The things to watch in the third-quarter 10-Q are: how the company financed itself after June 30; whether any ForSeeCon or OncoX milestone cash actually arrives; whether the $500,000 Lind obligation and the $1.74 million of accrued contractor costs are paid down or keep growing; whether the BioKey distribution gets a new date; and whether ABV-1519 and ABV-1703 really start in the fourth quarter or slip, which would signal that funding remains the binding constraint on the pipeline.